Table 1.
Patients’ characteristics
| Characteristic | Patients (n=40) |
|---|---|
| Median age at enrollment, years (range) | 61.5 (38–75) |
| Race/ethnicity, no. (%) | |
| Caucasian | 36 (90) |
| African American | 3 (7.5) |
| Hispanic | 1 (2.5) |
| Clinical T stage, no. (%)* | |
| T2b | 5 (12.5) |
| T2c | 5 (12.5) |
| T3a | 9 (22.5) |
| T3b | 14 (35) |
| T4 | 7 (17.5) |
| Lymph nodes status, no. (%)* | |
| Suspected** | 12 (30) |
| N1 | 21 (52.5) |
| M1a | 7 (17.5) |
| Biopsy Gleason score, no. (%) | |
| 7 | 3 (7.5) |
| 8 | 7 (17.5) |
| 9 | 27 (67.5) |
| 10 | 3 (7.5) |
| PSA before presurgical therapy, ng/mL (range) | 26.7 (1.4–479.5) |
| >25 | 15 (37) |
| ≤25 | 26 (63) |
*
2002 American Joint Committee on Cancer (AJCC) staging system.
**
Features in the primary tumor implying very high risk for lymph node dissemination (see Materials and Methods, Patients and Treatment section for description.